Tracy Onal, DO
Neuromusculoskeletal Medicine, Sports Medicine · East Islip, NYNPI 1508962002
Payments from drug & device makers
Across 438 payments — averaging $18.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$920
- AstraZeneca$893
- AbbVie$815
- GSK$782
- Novo Nordisk$774
- Pfizer$650
- plus $3K from 34 others
What the payments were for
- Food & beverage$8,09699%
- Education$851%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 54 | $920 |
| AstraZeneca | 48 | $893 |
| AbbVie(2 entities) | 42 | $815 |
| GSK | 42 | $782 |
| Novo Nordisk | 46 | $774 |
| Pfizer | 30 | $650 |
| Boehringer Ingelheim | 27 | $524 |
| Amarin Pharma, Inc. | 19 | $352 |
| Daiichi Sankyo Inc. | 17 | $302 |
| Johnson & Johnson | 14 | $257 |
| Merck | 15 | $208 |
| Otsuka America Pharmaceutical, Inc. | 9 | $185 |
| Esperion Therapeutics, Inc. | 8 | $157 |
| Boston Scientific | 4 | $148 |
| Amgen | 7 | $140 |
| Abbott | 7 | $125 |
| Currax Pharmaceuticals LLC | 6 | $112 |
| Kowa Pharmaceuticals America, Inc. | 7 | $106 |
| Exact Sciences | 5 | $98 |
| Idorsia Pharmaceuticals US Inc | 4 | $83 |
| Bausch Health US, LLC | 3 | $55 |
| Genentech USA, Inc. | 3 | $48 |
| Shield Therapeutics Inc | 2 | $45 |
| Intra-sana Laboratories | 2 | $43 |
| Lundbeck LLC | 2 | $38 |
| Medicomp Inc | 1 | $30 |
| Biohaven Pharmaceuticals, Inc. | 1 | $29 |
| Corcept Therapeutics | 1 | $26 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| Sumitomo Pharma America, Inc. | 1 | $25 |
| Astellas Pharma US Inc | 1 | $23 |
| Smith+Nephew | 1 | $22 |
| Renalytix AI, Inc. | 1 | $21 |
| Avvisto Therapeutics, LLC | 1 | $20 |
| Arbor Pharmaceuticals, Inc. | 1 | $19 |
| Evoke Pharma, Inc. | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Averitas Pharma Inc. | 1 | $17 |
| Qiagen, LLC | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
How this compares
$8,181 in reported general payments places this provider in the 85th percentile of 21 neuromusculoskeletal medicine, sports medicine providers in New York.
See all neuromusculoskeletal medicine, sports medicine providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 60 | $80,016 |
| EliquisApixaban | 39 | $44,238 |
| FarxigaDapagliflozin Propanediol | 27 | $37,853 |
| JardianceEmpagliflozin | 21 | $31,324 |
| RybelsusSemaglutide | 13 | $30,607 |
| JanuviaSitagliptin Phosphate | 22 | $29,622 |
| MounjaroTirzepatide | 27 | $29,116 |
| MyrbetriqMirabegron | 18 | $14,820 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $12,609 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $9,637 |
| VascepaIcosapent Ethyl | 11 | $5,847 |
| Levothyroxine Sodium | 208 | $4,148 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 112 | $3,904 |
| Metoprolol Succinate | 178 | $3,023 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $2,694 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $774 | $110,62273 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $893 | $47,49039 claims |
| PfizerEliquis | $650 | $44,23839 claims |
| Boehringer IngelheimJardiance | $524 | $31,32421 claims |
| MerckJanuvia | $208 | $29,62222 claims |
| Lilly USA, LLCMounjaro | $920 | $29,11627 claims |
| Astellas Pharma US IncMyrbetriq | $23 | $14,82018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 21 neuromusculoskeletal medicine, sports medicine providers in New York.
Other neuromusculoskeletal medicine, sports medicine in East Islip
- Jai PerumalNew York$235K
- David DinesUniondale$166K
- Marshall KeilsonBrooklyn$8K
- Aric HausknechtNew York$3K
- Brian NeriEast Meadow$3K
- Craig TitleNew York$889
- Libi GalmerJackson Heights$861
- Donald NennoBuffalo$745
- Shaik SanaiOceanside$419
- Jeffrey CohenNew York$269
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.